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ABSTRACT  27 
Alport syndrome is a hereditary glomerulopathy caused by a mutation in type 28 
IV collagen genes, which disrupts glomerular basement membrane, leading to 29 
progressive glomerulosclerosis and end-stage renal failure. There is at 30 
present no cure for Alport syndrome and cell-based therapies offer promise to 31 
improve renal function. Here, we found that human first trimester fetal 32 
chorionic stem cells (CSC) are able to migrate to glomeruli and differentiate 33 
down the podocyte lineage in vitro and in vivo. When transplanted into 7-week 34 
old Alport 129Sv-Col4a3tm1Dec/J (-/-) mice, a single intraperitoneal injection of 35 
CSC significantly lowered blood urea and urine proteinuria levels over the 36 
ensuing two weeks. In addition, nearly two thirds of transplanted -/- mice 37 
maintained their weight above the 80% welfare threshold, with both males and 38 
females weighing more than aged-matched non-transplanted -/- mice. This 39 
was associated with less renal cortical fibrosis and interstitial inflammation 40 
compared to non-transplanted mice, as shown by reduction in murine CD4, 41 
CD68 and CD45.2 cells. Transplanted CSC homed to glomeruli, where they 42 
expressed CR1, VEGFA, SYNAPTOPODIN, CD2AP and PODOCIN at the 43 
RNA level, and produced both PODOCIN, CD2AP and COLIVα3 proteins in 44 
non-transplanted -/- mice, suggesting indicating that CSC have adopted a 45 
podocyte phenotype.  Together, these data indicate that CSC may be used to 46 
delay progression of renal pathology via a combination of anti-inflammatory 47 
effects and potentially replacement of the defective resident podocytes.  48 
 49 
50 
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 51 
INTRODUCTION 52 
 53 
Alport syndrome (AS) is a genetic chronic kidney disease affecting 1 in 5,000 54 
individuals. Initially, AS manifests with haematuria, proteinuria and increased 55 
blood pressure, with progressive decline in renal function leading to end-stage 56 
renal failure requiring replacement therapy. People with AS also suffer from 57 
progressive hearing loss, anterior lenticonus, and macular flecks. AS is 58 
caused by mutations in the type IV collagen genes encoding the a3/a4/a5 59 
chains, which are produced exclusively by podocytes [1]. These mutations 60 
affect the correct assembly of heterotrimeric ColIVa3/a4/a5 chains in the 61 
glomerular basement membrane (GBM) and result in the GBM failing to 62 
mature from the embryonic ColIVa1/a1/a2  type. Persistence of the immature 63 
ColIVa1/a1/a2 GBM leads to its thickening and splitting, causing progressive 64 
tubulointerstitial fibrosis and renal failure [1]. The only current treatment for AS 65 
is blockade of the renin-angiotensin system, and proposed treatments include 66 
collagen receptor blockade, anti-microRNA therapy, and stem cell therapy [2]. 67 
The rationale of stem-based therapy is that stem cells isolated from healthy 68 
donors will migrate and engraft in renal glomeruli, where they may 69 
differentiate into functional podocytes producing new functional GBM. We 70 
previously showed that human first trimester fetal blood-derived mesenchymal 71 
stem cells (MSC) injected intraperitoneally into fetal mouse recipients 72 
migrated to the kidneys where they engrafted in renal glomeruli [3]. However, 73 
phenotype rescue by direct cell replacement is challenged by the low level of 74 
donor cell engraftment and poor differentiation capacity of the donor cells [4].  75 
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Col4a3tm1Dec/J mice are deficient in collagen a3(IV) chains, and suffer from 76 
progressive glomerulosclerosis, with thickening and lamellation of the 77 
glomerular basement membrane GBM, segmental glomerular scarring, 78 
tubular atrophy, tubulo-interstitial fibrosis and inflammation [5]. The rate of 79 
disease progression depends on the genetic background. On a 129Sv 80 
background (129Sv-Col4a3tm1Dec/J mice), inactivation of col4a3 leads to 81 
proteinuria by 35 days, elevated blood urea from 50 days onwards, and end 82 
stage renal failure by 66 days; whereas on a C57BL/6 background, 83 
(C57BL/B6-Col4a3tm1Dec/J mice), these events occur later at 110, 150 and 84 
194 days respectively [6].  85 
  86 
We previously showed that whole bone marrow from wild type Col4a3+/+ (+/+) 87 
mice transplanted into Col4a3–/– (-/-) mice produced the missing ColIVa3 88 
chain, and contributed to improved renal function. However, transplantation of 89 
expanded mesenchymal stem cells (MSC) from +/+ mice into -/-mice failed to 90 
improve renal function, suggesting either that culture conditions did not 91 
maintain cellular plasticity of bone marrow MSC or that other cells, such as 92 
hemopoietic stem cells, were involved in restoring renal function [7].  Using a 93 
similar model, Sugimoto et al. reported partial restoration of Col4a3 chain 94 
expression, as well as improvement of glomerular structure and kidney 95 
histology following wild-type bone marrow transplant [8]. Le Bleu et al. also 96 
showed that improvement of renal function in ColIVa3-/- mice was associated 97 
with the expression of the missing a3 chain of type IV collagen [9]. In all 98 
cases the origin of the cells responsible for the improved renal function was 99 
not established, but the results suggest that repair of GBM architecture and 100 
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glomerular integrety is attributable to expression of the collagen type IV a3 101 
chain from podocyte-differentiated donor cells. Using a different AS mouse 102 
model, i.e. ColIVa5-/- mice, Sedrakyan et al. suggested that mouse stem cells 103 
isolated from amniotic fluid delayed interstitial fibrosis and progression of 104 
glomerular sclerosis, ameliorating the decline in kidney function [4]. However, 105 
donor cells failed to differentiate into podocytes and produce the collagen 106 
IVa5 chain, suggesting that improved renal function may have been achieved 107 
via production of anti-inflammatory cytokines.  108 
The placenta is a potential source of readily obtainable stem cells throughout 109 
pregnancy. We recently isolated and characterized human fetal stem cells 110 
derived from first trimester chorion (i.e. chorionic stem cells, CSC)10. CSC 111 
have a spindle-like morphology, are capable of tri-lineage differentiation 112 
(osteogenic, adipogenic and chondrogenic) and demonstrate high tissue 113 
repair in vivo [10]. Over 95% of the cell population lack expression of CD14, 114 
CD34 and CD45 but express the mesenchymal markers CD105, CD73, 115 
CD44, vimentin, CD29, and CD90, with a subset of cells also expressing the 116 
pluripotency markers NANOG, SOX2, cMYC, KLF4, SSEA4, SSEA3, TRA-1-117 
60, and TRA-1-81 and being able to form embryo bodies containing cells from 118 
the three germ lineages. 119 
In this study, we provide evidence that human CSC can be differentiated 120 
down the podocyte lineage in vitro and in vivo, and delay progression of renal 121 
pathology when injected in ColIVa3-/- mice, preventing weigt loss and 122 
decreasing levels of cortical fibrosis and interstitial inflammation.    123 
 124 
 125 
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MATERIAL AND METHODS 126 
 127 
Animals.   128 
Alport (129-Col4a3tm1Dec/J) mutant (Col4a3–/–) and wild type (Col4a3+/+) mice 129 
(Jackson Laboratory) were housed in filter cages with a 12:12 hour light-dark 130 
cycle (21°C), with water and wet chow (Purina) ad libitum, to avoid 131 
dehydration which can affect blood urea measurements.  Mice were weaned 132 
at 30±1 days and culled at 9 weeks of age. All animals were handled in 133 
accordance with good animal practice as defined by the British Home Office 134 
Animal Welfare Legislation, and animal work was approved by the Institutional 135 
Research Ethics Committee (Imperial College London, UK). 136 
 137 
Glomeruli isolation.   138 
Kidneys from wild type and Alport mice were pushed through a series of 139 
sieves (pore sizes 150 µm, 106 µm and 45 µm) using the plunger of a 20 ml 140 
syringe. Glomeruli retained on the 45 µm sieve were collected into a tube and 141 
centrifuged at 1000 RPM for 10 minutes. 142 
 143 
Cell culture.   144 
Collection of surplus human chorionic villi samples was approved by the 145 
Research Ethics Committees of Hammersmith & Queen Charlotte’s Hospital 146 
and of University College London Hospital (UCLH) in compliance with national 147 
guidelines (Polkinghorne). CSC were selected by adherence to plastic, further 148 
expanded at 10,000 cells/cm2 at 37°C in 5% CO2 incubator, and studied at 149 
passage 4-8. Their fetal origin was confirmed by FISH for X and Y 150 
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chromosomes on male samples. The cells were fully characterised as 151 
previously reported [10], showing the characteristics of stromal MSC-like cells, 152 
i.e. capacity to differentiate down the osteogenic, adipogenic and 153 
chondrogenic pathway, and expression of CD73, CD90 and CD105. CSC 154 
were cultured for three weeks in Dulbecco’s modified Eagle’s medium-high 155 
glucose (Invitrogen) supplemented with 10% fetal bovine serum (BioSera), 156 
100 IU/mL penicillin, and 100 µg/mL streptomycin (Invitrogen), i.e. growth 157 
medium (D10) on non-coated plastic dishes, or on plastic dishes coated with 158 
human type IV collagen (Sigma).  159 
Temperature-sensitive conditionally-immortilized human podocyte cell line, 160 
derived by Saleem et al. from fresh normal human pediatric kidney 161 
specimens, were used as positive controls (gift from Moin Saleem, University 162 
of Bristol, Bristol, UK). These cells were originally by incorporating a 163 
temperature-sensitive SV40 gene that enables the cells to proliferate at a 164 
permissive temperature (33°C) and to differentiate at a non-permissive 165 
temperature (37°C), as evidenced by cell morphology and up-regulation of 166 
nephrin, synaptopodin, podocin and VEGFA expression [11]. The podocytes 167 
were cultured for 21 days at 37°C in 6-well plates in RPMI 1640 medium 168 
supplemented with glutamine (Invitrogen, Paisley, UK), 10% fetal calf serum 169 
(Biosera, East Sussex, UK), antibiotics and 1% insulin transferrin sodium 170 
selenite (Sigma). 171 
 172 
Fluorescence immunostaining and confocal microscopy.   173 
CSC were grown exponentially on 10-mm coverslips before being fixed in 4% 174 
PFA, 250 mM HEPES (pH 7.6; 10 min, 4°C), re-fixed in 8% PFA, 250 mM 175 
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HEPES (pH 7.6; 50 min, 4°C) and rinsed 3X with PBS. After fixation, the cells 176 
were incubated (30 min) with 20 mM glycine in PBS, blocked (1 h) with PBS+ 177 
(PBS supplemented with 1% BSA, 0.2% fish skin gelatin, 0.1% casein; pH 178 
7.6), incubated (2 h) with Anti- NHPS2 or Podocin (Sigma, 1:1,000) in PBS+, 179 
washed (5X over 1.5 h) in PBS+, incubated (1 h) with secondary antibodies 180 
(Alexa 488 goat anti rabbit) in PBS+, rinsed (overnight, 4°C) in PBS+, and 181 
mounted in VectaShield labelled with DAPI (Vector Labs). Fluorescence 182 
confocal laser scanning microscopy images were collected on a Leica TCS 183 
SP5 (X400 PL APO oil objective) and transferred to Adobe Photoshop (Adobe 184 
Systems).  185 
 186 
Chemotaxis assay.   187 
CSC suspension (100 µl of 107 cells/ml in DMEM-0.5% BSA) was placed in 188 
the upper compartment of a chemotaxis chamber. Chemoattractants 189 
(glomeruli from +/+ or -/- mice, or DMEM-0.5% BSA) were placed in the lower 190 
compartment, separated by a 8 µm polycarbonate filter (Neuroprobe). The 191 
cells were allowed to undergo chemotaxis (1 hour).  The filter was then 192 
removed, washed, fixed and stained (1% hematoxylin) (Sigma). Ten random 193 
fields were counted at X40 magnification by a blinded observer (triplicates). 194 
The migration index (MI) was calculated as the ratio of the number of cells 195 
migrating towards the chemoattractant to the number of cells migrating 196 
towards media alone.  197 
 198 
Cell transplantation.   199 
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Cells (106 in 10 µl PBS, pooled from 5 different donors to reduce inter-donor 200 
differences) were injected intraperitoneally in 7 week-old Col4a3–/– (-/-) or wild 201 
Col4a3+/+ (+/+) (n=25 per group). Animal weight was recorded 3 times per 202 
week and mice were culled 2 weeks after transplantation or when weight loss 203 
exceeded 20% of the maximum previously achieved weight, as mandated by 204 
the British Home Office.  205 
 206 
Quantitative real time RT-PCR (QRT-PCR).   207 
Total RNA (n=8 mice per group) was extracted from the glomeruli using 208 
TRIzol (Invitrogen) and cDNA synthesized using random primers and 1 µl of 209 
200 U M-MLV Reverse Transcriptase in the presence of dNTPs (Promega 210 
Corp.) (10 min, 75°C; 120 min, 42°C and 10 min, 75°C).  QRT-PCR was 211 
performed with the ABI Step-One Plus Sequence Detector (Applied 212 
Biosystems). We used primers amplifying sequences of the b-actin gene 213 
(accession number: NM_001101) present in humans but not in mice to 214 
determine the amount of human cellular cDNA in samples (primer specificity 215 
confirmed by absence of amplification of mouse cDNA), and primers common 216 
to both human and mouse to determine the total cDNA in each sample, as 217 
previously described [12]. For both sets, the absence of dimer formation was 218 
confirmed using Dissociation Curves 1.0 software (Applied Biosystems).  219 
Human:mouse chimerism was estimated as a ratio. Serial dilution of human 220 
cDNA in mouse cells formed the calibration curves. The primer sequences are 221 
shown in Table 1.  222 
 223 
Histology.   224 
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Fresh kidneys (n=6 mice) were fixed in Bouin’s fixative (Sigma) for 4 hours, 225 
dehydrated using serial dilutions of ethanol, embedded in wax, sectioned and 226 
stained with Picrosirius red stain. Five random non-overlapping fields were 227 
assessed at X200 magnification by a blinded observer, under polarised or 228 
white light with an Olympus BX51 microscope.  229 
 230 
Immunohistology.   231 
Fresh kidneys were removed and fixed in a solution containing 1% PFA, 232 
0.075M L-Lysine, 0.01M Sodium Periodate and 0.037M Phosphate buffer (all 233 
reagents from Sigma) for 4 hours at 4°C. Tissues were then stored overnight 234 
into 7% sucrose in PBS (Sigma) at 4°C, immersed in OCT compound (VWR) 235 
and snap frozen before being stored at -80°C for further analysis. For 236 
immunofluorescence, 4 μm sections were air dried (2 hours), fixed in acetone 237 
(10 min, 4°C), air dried for a further 2 hours and denatured (1 hour, 4°C) using 238 
a solution of 6M Urea and 0.1M Glycine in PBS (pH 3.5, all reagents from 239 
Sigma). Slides were then washed with PBS and incubated overnight at 4°C 240 
with a Col4a3 primary antibody diluted 1:2000 in 7% non-fat dry milk. The 241 
Col4a3 antibody (kindly donated by Dr Dominic Cosgrove, Boys Town 242 
National Research Hospital, Omaha, NE) is an affinity purified rabbit 243 
polyclonal antibody raised against a peptide mapping the NC1 region of 244 
collagen α3 Type IV. This antibody has been tested for cross-reactivity by the 245 
provider and reacts with human and mouse [14]. The presence of donor cells 246 
was visualised using a rabbit monoclonal antibody raised against human 247 
vimentin (Abcam ab137867). Slides were then washed in PBS, incubated at 248 
room temperature for 1 hour with a FITC-conjugated secondary antibody, 249 
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washed with PBS and mounted with Vectashield containing DAPI (Vector 250 
Laboratories, Peterborough, UK) for visualisation using a confocal laser-251 
scanning microscope Leica TCS SP5 (x1000 PL APO oil objective; Leica, 252 
Wetzlar, Germany). 253 
 254 
Immunohistochemistry.   255 
Immunoperoxidase staining for the macrophage/monocyte T-helper cell 256 
marker CD4 (BD Biosciences), the leucocyte marker CD45.2 (eBiosciences) 257 
and the macrophge marker CD68 (Abcam) was performed on PLP-fixed 258 
kidney cryostat sections (4μm). Sections were incubated overnight at 4°C with 259 
primary antibody. For the biotin-conjugated CD45.2 antibody, endogenous 260 
biotin and avidin were blocked prior to the addition of the primary antibody, 261 
using biotin and avidin block solutions respectively (Vector Labs). Sections 262 
were then washed with PBS, incubated with the appropriate HRP-conjugated 263 
secondary antibody (Golden Bridge International), washed with PBS and 264 
visualised using DAB. The sections were then counterstained with 265 
hematoxylin, dehydrated and mounted using DPX (Sigma). 266 
 267 
Blood urea analysis.   268 
Blood samples were centrifuged at 1,300 g (10 min, 4°C) and the supernatant 269 
was stored at -80°C until analysis. Urea was measured using a urea/ammonia 270 
detection kit (R-Biopharm), according to the manufacturers instructions. All 271 
samples were analysed at the same time to avoid batch variation. 272 
 273 
Measurement of proteinuria/hematuria.   274 
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Urine was collected from 9 week-old mice and proteinuria was quantitatively 275 
measured using mouse albumin and creatinine ELISA (albumin urinary level / 276 
creatinine urinary level) (Exocell), according to the manufacturers instructions. 277 
assessed for the presence of protein or erythrocytes by dipstick analysis 278 
(Siemens Healthcare, Surrey, UK).  Results were based on color change and 279 
ranged from 0/trace to ++++, according to the manufacturer’s detection guide.  280 
Controls included +/+ non-transplanted mice (negative control) and -/- non-281 
transplanted mice (positive control).  Analysis was performed by two 282 
observers blinded as to whether each sample was from transplanted or non-283 
transplanted -/- or +/+ groups.   284 
 285 
Western Blotting.   286 
Total protein was extracted using RIPAE buffer containing protease inhibitor 287 
cocktail and PMSF (Sigma). Protein concentrations were determined using 288 
the BCA assay (Thermo-Scientific) with BSA as standard. Proteins were run 289 
on 8% SDS-PAGE, transferred to nitrocellulose membranes, blocked with milk 290 
and incubated with primary antibodies for human-specific COLIVa3 (160-190 291 
kDa), PODOCIN (42 kDa, Santa Cruz) and CD2AP (71 kDa, Millipore).  292 
Membranes were incubated with secondary HRP-conjugated anti-goat IgG 293 
(Santa Cruz) and proteins detected using enhanced chemiluminescence 294 
(Thermo-Scientific). GAPDH was used as a loading control (Millipore).  295 
 296 
Statistical analysis.   297 
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Data are expressed as mean±SEM (standard error) or median and range. 298 
Parametric and non-parametric statistics were applied after testing 299 
distributions on histograms.  P < 0.05 was considered significant. 300 
 301 
 302 
RESULTS 303 
 304 
CSC cultured on human type IV collagen or co-cultured with glomeruli 305 
express podocyte markers and migrate to glomeruli in vitro. 306 
CSC were cultured for three weeks in growth medium (D10), either on non-307 
coated plastic dishes, on plastic dishes coated with human collagen IV (CSC 308 
on COLIV). Alternatively, CSC were co-cultured without cell contact, with 309 
freshly-isolated COL4a3-/- and COL4a3+/+ glomeruli (CSC-glomeruli co-310 
culture). After 3 weeks of culture, the expression level of various podocyte 311 
markers was analysed by QRT-PCR (Figure 1A). The podocyte line 312 
expressed NEP HRIN, a gene involved in renal filtration; PODOCIN, 313 
expression of which is restricted to mature podocytes; VEGFA, produced 314 
during kidney morphogenesis to guide endothelial cells towards glomeruli; 315 
SYNAPTOPODIN, an actin-associated gene; CD2AP, which regulates the 316 
translocation of dendrin to reorganize podocyte cytoskeleton and stabilize the 317 
slit diaphragm; and CR1, complement receptor 1 which protects podocytes 318 
from complement attack. The expression of these genes was almost 319 
undetectable in CSC cultured alone in growth medium on non-coated dishes.  320 
In contrast, the expression of all markers was upregulated when CSC were 321 
cultured on dishes coated with human collagen IV. Expression of NEPHRIN, 322 
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SYNAPTOPODIN, and CR1 was further up-regulated when the cells were co-323 
cultured with -/- glomeruli, although PODOCIN expression was lower. The 324 
expression levels of VIMENTIN and FIBRONECTIN remained unchanged in 325 
CSC cultured on Collagen Type IV or by co-culture with glomeruli (data not 326 
shown). Confocal immunofluorescnce showed that CSC cultured for 3 weeks 327 
on human type IV collagen or co-cultured with -/- glomeruli expressed 328 
PODOCIN at a protein level (Figure 1B). These data indicate that CSC have 329 
the potential to differentiate down the podocyte lineage. Next, we used a 330 
chemotaxis assay where CSC were allowed to migrate for 1h towards freshly 331 
isolated Col4a3-/- (-/-) or Col4a3+/+ (+/+) glomeruli ex vivo. CSC did not 332 
passively migrate towards growth medium (GM) alone, but showed high 333 
chemotaxis towards +/+ glomeruli and significantly greater chemotaxis 334 
towards -/- glomeruli (9.5±1.5 MI vs. 21.1±2.6 MI respectively) (Figure 1C). 335 
These results indicate that -/- glomeruli produce soluble factors that may 336 
stimulate migration and differentiation of CSC, and rationalize the use of CSC 337 
for the treatment of AS. 338 
 339 
CSC transplanted into -/- mice engrafted into glomeruli, expressed 340 
podocyte markers, and produce PODOCIN and the missing Col4a3 341 
protein. 342 
We injected 106 CSC intraperitoneally into 7 week old -/- and +/+ mice and 343 
assessed the fate of donor cells 2 weeks later. CSC injection was performed 344 
at 7 weeks postnatally because analysis of the disease history in -/- mice 345 
revealed the presence of blood and protein in urine at this age, whereas the 346 
levels of blood urea, which is a robust measure of renal function in mice, was 347 
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still comparable to the values found in +/+ mice. Donor cell engraftment in 348 
isolated glomeruli was determined by QRT-PCR using human-specific and 349 
non-specific primers for the housekeeping gene b-actin, as previously 350 
described13. Results showed that transplanted CSC homed to glomeruli, with 351 
10.8 fold higher engraftment in -/- (n=8) compared to +/+ glomeruli (n=8) 352 
(Figure 2A). Using human-specific antibody agains vimentin protein, 353 
histological analysis of kidney sections from transplanted and non-354 
transplanted -/- mice revealed the presence of donor CSC in glomeruli, with 355 
some donor cells being also visible outside the the glomeruli of CSC-356 
transplanted -/- mice (Figure 2B). Engrafted CSC expressed the podocyte 357 
markers CR1, VEGFA, SYNAPTOPODIN and CD2AP (Figure 2C). Human-358 
specificity of the primers was verified using RNA from kidneys of -/- non-359 
transplanted mice, which showed absence of amplification. At the protein 360 
level, engrafted CSC produced PODOCIN, CD2AP and COL4A3, which are 361 
absent in non-transplanted -/- and +/+ mice (Figure 2D and 2E). 362 
 363 
Improvement of the -/- phenotype. 364 
Non-transplanted -/- mice (n=25) progressively lost weight between 7 and 10 365 
weeks. By 9 weeks of age, 63% mice dropped their weight below the 20% 366 
endpoint level mandated by the British Home Office and had to be culled. In 367 
contrast, all CSC-transplanted -/- mice (n=48) maintained their weight until 9 368 
weeks (Figure 3A), at which age both transplanted -/- males and females 369 
were heavier than age- and sex-matched non-transplanted -/- mice, with their 370 
weight being similar to wild-type +/+ mice (Figure 3B).   371 
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Next, we measured blood urea in non-transplanted +/+ and -/- mice over 90 372 
days. Levels remained under 20 mmol/l until day 90 in +/+ mice (upper panel 373 
of Figure 3C, red dots, n=41), whilst all -/- mice showed elevated blood urea 374 
levels by 58 days of age (lower panel of Figure 3C, blue dots, n=45). In 375 
contrast, urea levels were lower in 9 week-old -/- mice transplanted with CSC 376 
two weeks before than in non-transplanted -/- mice (18.8±2.0 mmol/L, n=25 377 
vs. 29.9±0.7 mmol/L, n=10; mean±SEM, P<0.01), with 64% of transplanted -/- 378 
mice showing levels similar to +/+ mice (Figure 3D).  However, despite 379 
transplantation of CSC being associated with lower blood urea levels, 380 
proteinuria and hematuria, which were already elevated in -/- mice at the time 381 
of cell therapy, remained unchanged following CSC-transplantation (data not 382 
shown). Quantification of urine proteinuria (albumin / creatining level) revealed 383 
a significant reduction in -/- mice transplanted with CSC compared to their 384 
non-transplanted counterparts (35.6±1.8, n=21 vs. 47.5±3.2, n=16; 385 
mean±SEM, P<0.01) (Figure 3E).  386 
 387 
CSC transplantation lowered tubulointerstitial fibrosis and reversed 388 
cortical inflammation. 389 
We next measured tubulointerstitial fibrosis within the cortex using Picrosirius 390 
red staining (PSR). PSR in kidneys from CSC-transplanted -/- mice was lower 391 
than levels found in non-transplanted -/- mice (0.089±0.0018, n=6 vs. 392 
0.040±0.0015, n=6, P<0.001), indicating a decrease in tubulointerstitial 393 
fibrosis (Figure 4A and 4B). Quantification of renal inflammation showed that 394 
CSC transplantation reduced the number of glomerular T-helper cells (anti-395 
CD4), macrophages (anti-CD68), and haematopoietic cells (anti CD45.2) in -/- 396 
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mice indicating a marked decreased in cortical inflammation (Figure 4C and 397 
4D).   398 
 399 
Col4a3 mutation down-regulated endogenous murine podocyte gene 400 
expression, and CSC transplantation partially restored renal mRNA 401 
expression levels.  402 
We next assessed whether the presence of exogenous cells modified gene 403 
expression of resident podocytes.  Results showed that expression of murine 404 
Nephrin, Podocin, Synaptopodin, Cd2ap, Cr1 and Vegfa was higher in the 405 
glomeruli of non-transplanted +/+ mice compared to non-transplanted -/- mice 406 
(Figure 5). However, CSC transplantation upregulated the renal mRNA 407 
expression of Nephrin, Podocin, Synaptopodin, Cd2ap and Vgfa, suggesting 408 
that the decrease in glomerular inflammation in transplanted mice was 409 
associated with restored podocyte activity.  410 
 411 
 412 
DISCUSSION 413 
 414 
Several studies have suggested that renal pathology in models of AS can be 415 
improved by cell therapy, although the mechanisms mediating these effects 416 
remain elusive, with conflicting results possibly attributable to variations in 417 
donor cell types. It is therefore essential to identify easily accessible sources 418 
of stem cells with high therapeutic potential for the treatment of AS [14]. In this 419 
study, we used human first trimester fetal chorionic stem cells (CSC), which 420 
are isolated from chorionic villi sampling in ongoing pregnancies and can be 421 
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expanded to high numbers ex vivo, while maintaining tissue repair potential10. 422 
For example, when transplanted into collagen type I-deficient mice, they 423 
reduced fracture rate and increased bone plasticity; and accelerated skin 424 
wound healing [10, 15].   425 
 426 
Col4a3–/– mice are a model of severe human Alport syndrome.  At 7 week of 427 
age, -/- Alport mice show high levels of proteinuria, but normal weight and 428 
blood urea. Over the next two weeks, blood urea rapidly increases, whilst 429 
body weight drops and mice show pronouced interstitial fibrosis and 430 
macrophage infiltration. We investigated the capacity of CSC to prevent 431 
glomerulopathy in 129Sv-Col4a3-/- mice.  We show that 9 week-old -/- mice 432 
transplanted with CSC two weeks before have significantly lower blood urea 433 
and urine proteinuria, compared to their non-transplanted counterparts. 434 
Although animal welfare restrictions prevented us from studying the clinical 435 
endpoint of survival, all transplanted -/- mice maintained their weight until 9 436 
week of age. This is important because improvement in renal histology is not 437 
necessarily associated with delay in death from renal failure [16]. However, 438 
the genetic backgroud of the Alport mice has a strong effect on the rate of 439 
disease progression [17]. Contrary to 129Sv-Col4a3tm1Dec/J (-/-) mice, which 440 
progressively lose weight and do not survive beyond 10 weeks of age, the 441 
survival time of homozygous mutant mice is extended to about 14 weeks of 442 
age in mice maintained on a mixed genetic background or to 25-30 weeks on 443 
the C57BL/6j background. Consequently, we suggest that the elevated blood 444 
urea and 20% weight loss we report may be considered as surrogates for 445 
end-stage renal failure. We found that proteinuria, which was already elevated 446 
 19 
at the time of cell injection, did not return to normal levels but did not increase 447 
further in transplanted -/- mice, whilst it increased in non-transplanted -/- mice 448 
. This was not surprising, since structural damage to the GBM would be 449 
unlikely to be reversed within 2 weeks. 450 
 451 
Increasing evidence from stem cell transplantation in acquired injury models 452 
points to the well characterised anti-inflammatory actions of exogenous stem 453 
cells making a major contribution to therapeutic results. For example, murine 454 
amniotic fluid cells transplanted into Col4a5-/- mice before the onset of 455 
proteinuria have been reported to modify the course of renal fibrosis, despite 456 
donor cells failing to differentiate into podocytes or produce collagen IVa54. 457 
Here, we found reduced renal fibrosis and cortical inflammation in 458 
transplanted mice, which may reflect the anti-inflammatory effect of donor 459 
cells or the replacement of defective renal cells. We also found that CSC 460 
migrated to the glomeruli, where they persisted over 2 weeks and expressed 461 
CR1, VEGFA, SYNAPTOPODIN, CD2AP and PODOCIN at the gene level, 462 
and produced PODOCIN, CD2AP and COLIVα3 proteins. which are missing 463 
in non-transplanted -/- mice. These data indicate that transplanted CSC have 464 
adopted a podocyte phenotype. However, focal staining for Col4a3 in the 465 
kidneys does not prove true GBM deposition, and it will be necessary to 466 
demonstrate assembly of the correct collagen type IV in the GBM to 467 
investigate whether the Col4a3 produced by CSC co-assemble with Col4a4 468 
and Col4a5 to improve GBM structure [18]. Similarly to our findings, LeBleu et 469 
al. found that wild-type bone marrow-derived cells transplanted into Col4α3 -/- 470 
mice improved renal histology and function, with donor cells differentiating into 471 
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VEGF and collagen IV-expressing podocytes [9]; and a recent study by Lin et 472 
al. demonstrates that secretion of α3α4α5(IV) heterotrimers is sufficient to 473 
slow disease progression by partially restoring the defective collagen network 474 
[19]. 475 
 476 
Interestingly, we also found that CSC transplantation stimulated resident 477 
podocyte activity, suggesting that the production of Col4a3 from donor cells 478 
act as a feed-back to modulate podocyte activity, possibly by releasing trophic 479 
factors that promote the differentiation and regeneration of endogenous 480 
podocyte progenitors to differentiate into mature podocytes. Although 481 
endogenous podocytes remain unable to express the correct form of Collagen 482 
type IV, stimulation of podocyte progenitors differentiation into podocytes by 483 
donor stem cells may contribute to the amelioration of filtration function [20]. 484 
Although it is often assumed that the presence of exogenous cells at the site 485 
of injury and their differentiation into target cell phenotypes accounts for the 486 
therapeutic effects observed, there is still a lack of evidence for the causality 487 
between the two. An increasing number of studies challenge the concept of 488 
donor cells acting as a building blocks to replace damaged endogenous cells 489 
and data suggest that beyond their potential as a source of cell replacement, 490 
stem cells also mediate paracrine treatment. In addition, data suggest that 491 
donor cells influence the complex cross-talk between resident cells and 492 
extracellular matrix. It is possible that exogenous stem cells reprogramme 493 
resident macrophages from an anti-inflammatory to a pro-inflammatory 494 
phenotype, as is the case in sepsis [21]. This mechanism might account for 495 
the therapeutic effects of wild type bone marrow that we previously reported7.  496 
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For example, blockade of tumour necrosis factor-alpha (TNF-a), a pro-497 
inflammatory cytokine, has been shown to ameliorate glomerulosclerosis and 498 
proteinuria in AS mice [22].  499 
We believe that CSC may have strong potential for the treatment of 500 
glomerulopathies and further studies are indicated to establish the precise 501 
mechanism of action of these cells in treatment of AS. 502 
 503 
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FIGURE LEGENDS 622 
Figure 1 | CSC cultured in permissive conditions express podocyte 623 
markers and migrate to glomeruli in vitro.  A. Quantitative real-time RT-624 
PCR using human-specific primers and showing expression of the podocyte 625 
markers NEPHRIN, SYNAPTOPODIN, PODOCIN, CD2AP, VEGFA, and CR1 626 
in a temperature-inducible differentiated podocyte cell line (grey bars), in 627 
mouse glomerular cells (black bars), in CSC cultured for three weeks either in 628 
growth medium (D10) on non-coated plastic dishes (green bars), on plastic 629 
dishes coated with human collagen IV (blue bars), and in CSC co-cultured 630 
with -/- glomeruli (red bars) and +/+ glomeruli (white bars).  Values are 631 
expressed as 2-DCT, with DCT = b-actin - gene of interest.  *** P<0.01 n=3 632 
samples per group, error bars are SEM.  B. Confocal immuno-fluorescence of 633 
CSC cultured for three weeks on human Type IV collagen and co-cultured 634 
with -/- glomeruli.  Anti-podocin marker was stained with FITC (green), and 635 
nuclei with DAPI (blue). X10 magnifications.  C. In vitro chemotaxis assay 636 
where CSC were allowed to migrate towards +/+ (clear bars) or -/- (red bars) 637 
freshly isolated glomeruli for 1 hour.  *** P<0.01, n=3 per group, error bars are 638 
SEM. 639 
 640 
Figure 2 | Transplanted CSC engrafted into -/- glomeruli and expressed 641 
podocyte markers.  A. Quantitative real-time RT-PCR showing expression of 642 
b-actin using human-specific primers in mouse glomeruli isolated from non-643 
transplanted -/- mice (black bar, 0), transplanted +/+ mice (red bars) and 644 
transplanted -/- mice (blue bars) mice.  *** P<0.001, n=8 animals per group, 645 
error bars are SEM.  Values were normalised to total b-actin using mouse-646 
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human non-specific primers (2-DCT).  B. Immunohistochemistry showing 647 
human-specific vimentin staining (brown) in the glomeruli of non-transplanted 648 
and transplanted -/- mice (counterstained with haematoxyllin), and human-649 
specific podocin in non-transplanted -/- mice.  X200, X400 and x40 650 
magnifications.  C. Quantitative real-time RT-PCR showing expression of 651 
podocyte markers (CR1, VEGFA, SYNAPTOPODIN, CD2AP) using human-652 
specific primers that do not amplify mouse sequences in CSC (black bars), 653 
and in the glomeruli of transplanted (green bars), non-transplanted (red 654 
values) -/- mice and in +/+ mice (blue values). Values were normalised to 655 
human-specific b-actin (DCT). n=8 per group, error bars are SEM.  D. 656 
Western blot showing detection of human-specific PODOCIN, CD2AP and 657 
COL4A3 protein within the glomeruli of transplanted and non-transplanted -/- 658 
mice, and non-transplanted +/+ mice. GAPDH was used as loading control.  659 
E. Immunofluorescence for COL4A3 in kidneys of non-transplanted and 660 
transplanted -/- mice.  Scale bar = 25 and 10 µm.   661 
 662 
Figure 3 | CSC transplantation prevented weight loss in -/- mice and 663 
reduced levels of blood urea and cortical fibrosis.  A. Percentage of 9 664 
week-old transplanted and non-transplanted -/- mice (n= 48 and 25, 665 
respectively) showing a weight loss above (white box, mice alive) or below 666 
(black box, mice culled before the age of 9 weeks) the 20% required for the 667 
Home Office to maintain mice alive (top graph).  B. Weight of 9 week-old non-668 
transplanted +/+ (n=15, red bars), non-transplanted -/- (n=10, blue bars) and 669 
transplanted -/- mice (n=8 per group, green bars), error bars are SEM.  * 670 
P<0.05.  C. Blood urea levels (mmol/L) in non-transplanted +/+ (upper panel, 671 
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red dots, n=41) and -/- mice (middle panel, blue dots, n=45) measured over 672 
90 days.  D. Blood urea levels in 9 week-old non-transplanted +/+ mice (red 673 
dots, n=10), non-transplanted -/- mice (blue dots, n=10), and CSC-674 
transplanted -/- mice (green dots, n=25).  Bars are mean and SEM.  *** 675 
P<0.001.  E. Urine proteinuria levels (albumin / creatinine ratios) in 9 week-old 676 
non-transplanted +/+ mice (red dots, n=21), non-transplanted -/- mice (blue 677 
dots, n=16), and CSC-transplanted -/- mice (green dots, n=21).  Bars are 678 
mean and SEM.  ** P<0.01. 679 
 680 
Figure 4 | CSC transplantation reduced cortical inflammation in -/- 681 
glomeruli.  A. Quantification of picrosirius red staining (PSR) within the renal 682 
cortical area of non-transplanted (blue bar) and transplanted (green bar) -/- 683 
mice, two weeks after transplantation.  *** P<0.0001, n=4 animals per group. 684 
5 independent fields were quantified per sample, data are expressed as area 685 
sum.  B. Polarised images of kidney sections from non-transplanted and 686 
transplanted -/- mice, stained with picrosirius red.  Scale bar 200μm.  C. 687 
Quantification of CD4, CD68 and CD45.2-positive staining within the cortical 688 
area of non-transplanted (blue bars) and transplanted (red bars) -/- mice. *** 689 
P<0.001, n=4 animals per group, error bars are SEM.  5 independent fields 690 
were quantified per sample, data are expressed as area sum.  D. 691 
Immunohistochemistry for mouse-specific anti-CD4, CD68 and CD45.2 692 
(brown) in the glomeruli of 9 week-old transplanted and non-transplanted -/- 693 
mice (counterstained in blue).  X200 magnification. 694 
 695 
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Figure 5 | Expression of endogenous murine renal markers is modulated 696 
by CSC transplantation. Quantitative real-time RT-PCR showing expression 697 
of podocyte markers using mouse-specific primers that do not amplify human 698 
sequences (Nephrin, Podocin, Vegfa, Synaptopodin, Cd2ap, Cr1), in the 699 
glomeruli of non-transplanted +/+ mice (red bars), non-transplanted -/- mice 700 
(black bars), and transplanted -/- mice (white bars).  Values were normalised 701 
to mouse-specific cyclophillin.  *** P<0.001, *P<0.05, n=8 per group, error 702 
bars are SEM. 703 
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Table 1 705 
List of primers used for RT-PCR and real-time RT-PCR 706 
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Table 1 
 
Gene Accession no. Primers (5’à3’) 
BMI1 NM_005180 F: CTGGTTGCCCATTGACAGC 
R: CAGAAAATGAATGCGAGCCA 
NEPHRIN NM_004646 F: CTCTGGAACCCGATTCTCTG 
R: TGGGTTTTATGGAGCTGACC 
SYNAPTOPODIN NM_007286 F: GGAGGATGATGGGGCAGC 
R: GGGTCGGAGCTGGGATAC 
PODOCIN NM_014625 F: TGGGGAATCAAAGTGGAGAG 
R: GAATCTCAGCTGCCATCCTC 
CD2AP NM_012120 F: CACATCCACAAACCAAAAACATT 
R: CTCCACCAGCCTTCTTCTACC 
VEGF-A NM_001025366 F:TCCTCACACCATTGAAACCA 
R:TTTTCTCTGCCTCCACAATG 
CR1 NM_000651 F: TGGCATGGTGCATGTGATCA 
R: TCAGGGCCTGGCACTTCACA 
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 723 
 724 
 725 
